A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
| العنوان: | A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020 |
|---|---|
| المؤلفون: | Martin C. Michel, Gizem Kayki-Mutlu |
| المصدر: | Naunyn-Schmiedeberg's Archives of Pharmacology |
| بيانات النشر: | Springer Berlin Heidelberg, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), 610 Medizin, New Drug Approvals, Review Article, Food and drug administration, First-in-indication, 03 medical and health sciences, 0302 clinical medicine, 610 Medical sciences, Pandemic, Drug Discovery, medicine, Animals, Humans, 030212 general & internal medicine, Intensive care medicine, Drug Approval, Pandemics, Pharmacology, First-in-class, Drug discovery, business.industry, United States Food and Drug Administration, COVID-19, General Medicine, United States, New drugs, Mechanism of action, Antisense oligonucleotides, Pharmacology, Clinical, medicine.symptom, business, 030217 neurology & neurosurgery, FDA |
| الوصف: | While the COVID-19 pandemic also affected the work of regulatory authorities, the US Food and Drug Administration approved a total of 53 new drugs in 2020, one of the highest numbers in the past decades. Most newly approved drugs related to oncology (34%) and neurology (15%). We discuss these new drugs by level of innovation they provide, i.e., first to treat a condition, first using a novel mechanisms of action, and “others.” Six drugs were first in indication, 15 first using a novel mechanism of action, and 32 other. This includes many drugs for the treatment of orphan indications and some for the treatment of tropical diseases previously neglected for commercial reasons. Small molecules continue to dominate new drug approvals, followed by antibodies. Of note, newly approved drugs also included small-interfering RNAs and antisense oligonucleotides. These data show that the trend for declines in drug discovery and development has clearly been broken. |
| اللغة: | English |
| تدمد: | 1432-1912 0028-1298 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb2f065bdbaac10c7fc5260394d41f8 http://europepmc.org/articles/PMC8051285 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3fb2f065bdbaac10c7fc5260394d41f8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14321912 00281298 |
|---|